Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$25.39 USD
-0.93 (-3.53%)
Updated Oct 13, 2025 04:00 PM ET
After-Market: $25.45 +0.06 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BEAM 25.39 -0.93(-3.53%)
Will BEAM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
Other News for BEAM
Slingshot Bullish appears for BEAM after 5.56% move
Pocket Pivot appears for BEAM after 3.22% move
HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target | BEAM Stock News
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Beam Therapeutics initiated with a Buy at Jefferies